147 related articles for article (PubMed ID: 27747761)
21. Knowledge, attitudes, and clinical practice of rheumatologists in vaccination of the at-risk rheumatology patient population.
McCarthy EM; Azeez MA; Fitzpatrick FM; Donnelly S
J Clin Rheumatol; 2012 Aug; 18(5):237-41. PubMed ID: 22832287
[TBL] [Abstract][Full Text] [Related]
22. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.
Harrold LR; Reed GW; Best J; Zlotnick S; Kremer JM
Rheumatol Ther; 2018 Dec; 5(2):507-523. PubMed ID: 30293218
[TBL] [Abstract][Full Text] [Related]
23. Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study.
Pappas DA; Brittle C; Mossell JE; Withers JB; Lim-Harashima J; Kremer JM
Rheumatol Int; 2021 Mar; 41(3):585-593. PubMed ID: 33258003
[TBL] [Abstract][Full Text] [Related]
24. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
Zhao J; Zhou W; Wu Y; Ji P; Yang L; Yan X; Zhang Z
BMC Med Inform Decis Mak; 2021 Mar; 21(1):83. PubMed ID: 33663487
[TBL] [Abstract][Full Text] [Related]
25. A Canadian survey of current methotrexate prescribing practices in rheumatoid arthritis.
Collins D; Bellamy N; Campbell J
J Rheumatol; 1994 Jul; 21(7):1220-3. PubMed ID: 7966061
[TBL] [Abstract][Full Text] [Related]
26. Survey on management strategies of rheumatoid arthritis in Saudi Arabia: a Saudi Society for Rheumatology Initiative.
Omair MA; Omair MA; Halabi H
Int J Rheum Dis; 2017 Sep; 20(9):1185-1192. PubMed ID: 26354409
[TBL] [Abstract][Full Text] [Related]
27. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
[TBL] [Abstract][Full Text] [Related]
28. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
29. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
[TBL] [Abstract][Full Text] [Related]
30. Management of temporomandibular joint arthritis in adult rheumatology practices: a survey of adult rheumatologists.
Ringold S; Tzaribachev N; Cron RQ
Pediatr Rheumatol Online J; 2012 Aug; 10(1):26. PubMed ID: 22906004
[TBL] [Abstract][Full Text] [Related]
31. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis.
Patel D; Shelbaya A; Cheung R; Aggarwal J; Park SH; Coindreau J
Adv Ther; 2019 Aug; 36(8):2086-2095. PubMed ID: 31148057
[TBL] [Abstract][Full Text] [Related]
33. Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis.
Curtis JR; Chen L; Danila MI; Saag KG; Parham KL; Cush JJ
J Rheumatol; 2018 Jan; 45(1):40-44. PubMed ID: 29142029
[TBL] [Abstract][Full Text] [Related]
34. Promoting physical activity in patients with rheumatoid arthritis: rheumatologists' and health professionals' practice and educational needs.
Hurkmans EJ; de Gucht V; Maes S; Peeters AJ; Ronday HK; Vliet Vlieland TP
Clin Rheumatol; 2011 Dec; 30(12):1603-9. PubMed ID: 21912880
[TBL] [Abstract][Full Text] [Related]
35. Variations and practice in the care of patients with rheumatoid arthritis: quality and cost of care.
DeMaria L; Acelajado MC; Luck J; Ta H; Chernoff D; Florentino J; Peabody JW
J Clin Rheumatol; 2014 Mar; 20(2):79-86. PubMed ID: 24561410
[TBL] [Abstract][Full Text] [Related]
36. Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.
Pundole X; Zamora NV; Siddhanamatha H; Lin H; Tayar J; Hong LC; Li L; Suarez-Almazor ME
Clin Rheumatol; 2020 Mar; 39(3):787-794. PubMed ID: 31853733
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
[TBL] [Abstract][Full Text] [Related]
38. Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.
Sherman MA; Kim H; Banschbach K; Brown A; Gewanter HL; Lang B; Perron M; Robinson AB; Spitznagle J; Stingl C; Syverson G; Tory HO; Spencer CH; Tarvin SE
Pediatr Rheumatol Online J; 2023 Jan; 21(1):3. PubMed ID: 36609397
[TBL] [Abstract][Full Text] [Related]
39. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.
Mease PJ; Stryker S; Liu M; Salim B; Rebello S; Gharaibeh M; Collier DH
Arthritis Res Ther; 2021 Sep; 23(1):236. PubMed ID: 34496952
[TBL] [Abstract][Full Text] [Related]
40. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
Mota LMHD; Kakehasi AM; Gomides APM; Duarte ALBP; Cruz BA; Brenol CV; de Albuquerque CP; Castelar Pinheiro GDR; Laurindo IMM; Pereira IA; Bertolo MB; Ubirajara Silva de Souza MPG; de Freitas MVC; Louzada-Júnior P; Xavier RM; Giorgi RDN
Adv Rheumatol; 2018 May; 58(1):2. PubMed ID: 30657071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
